AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 281 min read$CNMD

Conmed: Q3 Earnings Snapshot

Conmed Corp. (CNMD) reported Q3 profit of $19.8M, or 66c/share, beating estimates. Revenue was $335.6M. Full-year EPS guidance is $4.54-$4.61, with revenue of $1.36B-$1.37B. According to Zacks, analysts expected $1.04 per share.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 8:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Conmed: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CNMDBullishHigh
01

Why it matters

The earnings beat and higher-than-expected full‑year guidance provide a fresh catalyst for the stock, likely prompting buying interest.

02

Market read

First‑report earnings and guidance for a U.S. med‑tech firm, offering a clear trading signal.

03

What to watch

Potential supply‑chain constraints or upcoming regulatory reviews could temper upside.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Conmed Corp. (CNMD) is a medical technology company based in Largo, Florida.

Company-level read

Ticker impact

$CNMDBullishHigh confidence
Context

Conmed Corp. reported Q3 earnings beating estimates and provided full-year guidance above expectations.

Expected impact

upward pressure as market prices in the earnings beat and higher guidance

Evidence & confidence

The beat and guidance are fresh, material information that traders can act on immediately.

Market effects

Sector

Medical technology sector may see modest uplift from a larger peer's earnings beat.

Regional

U.S. small‑cap healthcare stocks could benefit from the positive surprise.

Global

Limited to investors focused on U.S. med‑tech equities.

Counterpoint

What could challenge this read

If guidance falls short of growth expectations, the stock could face disappointment despite the beat.

Key entities

  • Company
    Conmed Corp.

    Medical technology manufacturer reporting Q3 results.

Read at source← All news

StoryCONMED posts Q3 2026 results, beats adjusted EPS and lifts full‑year EPS guidance

Also covered by

5 outlets

Related articles

OCT 29
$CNMDMed

CONMED (CNMD) Q3 2026 Earnings Call Transcript

CONMED (CNMD) reported Q3 2026 net revenue of $335.6M, with organic growth of 6.7% YoY. Adjusted EPS was $1.04, exceeding expectations. AirSeal and Buffalo Filter drove sales growth, with AirSeal showing strong performance in robotic and laparoscopic surgery. The company remains optimistic about long-term growth prospects for these products.

finance.yahoo.com3 min
OCT 28
$CNMDMedAI 8/10

Conmed (CNMD) Q3 Earnings Top Estimates

Conmed (CNMD) reported Q3 earnings of $1.04 per share, beating estimates by $0.04. Revenue was $335.56M, missing estimates by 0.37%. The company has beaten EPS estimates four times in the last four quarters. Shares are up 16.3% YTD. The Zacks Rank for the stock is #3 (Hold).

finance.yahoo.com2 min
OCT 28
$CNMDHighAI 8/10

CONMED (NYSE:CNMD) posts Q3 2026 sales in line with estimates

CONMED (CNMD) reported Q3 2026 revenue of $335.6M, flat year-on-year but in line with estimates. Adjusted EPS of $1.04 beat estimates by 3.7%. The company reconfirmed its full-year revenue guidance of $1.36B and slightly raised its EPS guidance to $4.58. Operating margin decreased to 11.1% from 3.5% year-on-year. Long-term revenue growth has slowed, with a 6.7% CAGR over five years.

finance.yahoo.com2 min